Why the study?
Is linagliptin safe and well-tolerated in patients with type 2 diabetes mellitus, including those with renal impairment?
Is linagliptin safe and well-tolerated in patients with type 2 diabetes mellitus, including those with renal impairment?
Linagliptin offers a safe and well-tolerated treatment option for type 2 diabetes, particularly advantageous for patients with renal impairment as it requires no dose titration.
May support linagliptin without titration in renal impairment; leaves open prospective RCTs for confirmation.
INTRODUCTION: Established treatments for type 2 diabetes mellitus (T2DM) have side effects that limit their use in specific populations. New therapies with improved safety profiles are needed, especially because of the chronic and progressive nature of T2DM. AREAS COVERED: This review describes the overall safety and tolerability of linagliptin--a dipeptidyl peptidase-4 inhibitor that improves glycemic control without increasing risk for hypoglycemia and without weight gain. Specifically, the safety of linagliptin is evaluated in difficult-to-treat patients with T2DM, in relation to risk of cardiovascular (CV) events and acute pancreatitis, and in comparison with other antihyperglycemic drugs. EXPERT OPINION: Linagliptin is generally well tolerated in a broad range of patient populations. It can be used in patients with renal impairment without dose titration and may be a rational alternative treatment in this vulnerable population. Ongoing long-term trials are fully evaluating the CV and renal safety profile of linagliptin.
No takes yet. Share an insight, caveat, or question.
Anthony Barnett (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: